Qingwen Cheng

Qingwen Cheng holds the position of Sr. Scientist I at RemeGen Biosciences since April 2023, leading multiple antibody-drug conjugate projects aimed at developing monoclonal and bi-specific antibodies for cancer treatment. Prior to this role, Qingwen Cheng was a Scientist at Amgen from April 2004 to April 2023, where significant advancements in generating monocytes and macrophages from iPSC and differentiating hematopoietic stem cells were achieved. Earlier experience includes being an Associated Scientist at Tularik from April 1998 to March 2004, focusing on assays for G-protein coupled receptors and evaluating drug efficacy in diabetes and obesity models. Additionally, Qingwen Cheng served as a Research Associate at the University of California, Los Angeles from May 1998 to April 2001, contributing to research on chemotherapy-induced resistance and the immunogenicity of adenoviral vectors. Education was completed at Shanghai Second Medical University.